Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for 4142 from our risk checks.
Adimmune Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | NT$27.65 |
52 Week High | NT$38.85 |
52 Week Low | NT$25.00 |
Beta | 0.45 |
1 Month Change | 0.18% |
3 Month Change | -4.33% |
1 Year Change | -27.90% |
3 Year Change | -48.22% |
5 Year Change | 40.00% |
Change since IPO | -60.50% |
Recent News & Updates
Shareholder Returns
4142 | TW Biotechs | TW Market | |
---|---|---|---|
7D | 0.9% | 1.2% | -1.5% |
1Y | -27.9% | -9.5% | 25.5% |
Return vs Industry: 4142 underperformed the TW Biotechs industry which returned -9.5% over the past year.
Return vs Market: 4142 underperformed the TW Market which returned 25.5% over the past year.
Price Volatility
4142 volatility | |
---|---|
4142 Average Weekly Movement | 4.0% |
Biotechs Industry Average Movement | 4.9% |
Market Average Movement | 4.8% |
10% most volatile stocks in TW Market | 8.6% |
10% least volatile stocks in TW Market | 2.3% |
Stable Share Price: 4142 has not had significant price volatility in the past 3 months.
Volatility Over Time: 4142's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1965 | n/a | Steve Chan | www.adimmune.com.tw |
Adimmune Corporation manufactures and sells human vaccines in Taiwan. It offers AdimFlu-S, a quadrivalent influenza vaccine; tetanus toxoid alum precipitated product that is used for the prevention of tetanus after injury; Japanese encephalitis vaccines; Trivalent influenza vaccines; Quadrivalent influenza vaccine; Influenza A (H1N1) Virus Monovalent Vaccine; Tetanus Toxoid; and purified Tuberculin, as well as contract manufacturing services. The company was formerly known as Kuo Kwang Serum and Vaccine Manufacture Co., Ltd.
Adimmune Corporation Fundamentals Summary
4142 fundamental statistics | |
---|---|
Market cap | NT$11.59b |
Earnings (TTM) | -NT$574.85m |
Revenue (TTM) | NT$1.66b |
7.0x
P/S Ratio-20.3x
P/E RatioIs 4142 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
4142 income statement (TTM) | |
---|---|
Revenue | NT$1.66b |
Cost of Revenue | NT$1.26b |
Gross Profit | NT$400.53m |
Other Expenses | NT$975.38m |
Earnings | -NT$574.85m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.36 |
Gross Margin | 24.14% |
Net Profit Margin | -34.64% |
Debt/Equity Ratio | 43.0% |
How did 4142 perform over the long term?
See historical performance and comparison